Short answer
Protalix BioTherapeutics, Inc. (PLX) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Protalix’s quarter ended September 30, 2026.
Protalix BioTherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Protalix’s quarter ended September 30, 2026
- Business and clinical updates accompany the quarterly financial results
- Investors should review Exhibit 99.1 for financial figures and pipeline developments
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $21.9M and net income $4.0M, up from $17.9M and $2.4M year over year
- Nine-month revenue $75.6M, including $25.0M Chiesi milestone, versus $43.6M in 2025
- Nine-month net income $26.1M, or $0.31 diluted EPS, versus $1.1M net loss previously
- Cash, equivalents, and short-term deposits $48.5M, with no outstanding debt or warrants
- 2026 revenue guidance reaffirmed at approximately $78.0M to $83.0M, while PRX-115 Phase 2 results remain expected in the second half of 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protalix BioTherapeutics, Inc. 8-K filings
Get the next PLX 8-K as it lands
Follow PLX for push alerts, or ask the research agent what this filing means.